NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.
NovoCure Q2: revenue +16% ($183.6M beat), pazienti +18%, guidance 2026 $710-725M, ma trial glioblastoma fallito (no survival benefit). De-risking biotech indica shift verso market consolidation su prodotti approvati vs pipelines R&D rischioso; riflette dinamica medtech cruciale per strategie AI/healthcare.
NovoCure Ltd.
(NASDAQ:NVCR) shares rose in Friday’s premarket session before dropping after the company raised its full-year 2026 revenue outlook and reported second-quarter earnings and sales above analyst expectations.
The stock closed Thursday at $19.99, up 28.39%. • NovoCure stock is among today's weakest performers.
Why are NVCR shares down?
Earnings Beat Expectations NovoCure posted a loss of 13 cents per share, narrower than the 33 cent loss estimate.
Novocure stock broke out Thursday after reporting Street-beating, double-digit sales growth for its wearable cancer treatment.
Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms…
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger…
Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confirmed TTFields safety.
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
Novartis Bounds For Buy Point; Why Shares Are On The Rise
